insights_auto
Why is BAVA up 4.03%?
Dive Deeperchevron_right
BAVA:CPH
Bavarian Nordic A/S
DKKÂ 222.20
arrow_upward
+4.03%(+8.60) 1D
Sep 23, 5:00:00 PM GMT+2 · DKK
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
DKKÂ 214.60
High
DKKÂ 224.20
Low
DKKÂ 214.60
Mkt. cap
16.93B
Avg. vol.
217.02K
Volume
360.46K
52-wk high
DKKÂ 243.70
52-wk low
DKKÂ 171.30
Shares outstanding
79.27M
No. of employees
2K
Open
DKKÂ 214.60
High
DKKÂ 224.20
Low
DKKÂ 214.60
Mkt. cap
16.93B
Avg. vol.
217.02K
Volume
360.46K
52-wk high
DKKÂ 243.70
52-wk low
DKKÂ 171.30
Shares outstanding
79.27M
No. of employees
2K
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination. In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com